NASDAQ:NMTC NeuroOne Medical Technologies (NMTC) Stock Price, News & Analysis → What is Medicare Supplement Insurance? (From Tranzact) (Ad) Free NMTC Stock Alerts $1.11 -0.05 (-4.31%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$1.11▼$1.1650-Day Range$1.03▼$1.3852-Week Range$0.85▼$2.00Volume38,571 shsAverage Volume175,841 shsMarket Capitalization$28.78 millionP/E RatioN/ADividend YieldN/APrice Target$2.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get NeuroOne Medical Technologies alerts: Email Address NeuroOne Medical Technologies MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside98.2% Upside$2.20 Price TargetShort InterestHealthy1.40% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.01 out of 5 starsMedical Sector705th out of 908 stocksSurgical & Medical Instruments Industry77th out of 97 stocks 3.5 Analyst's Opinion Consensus RatingNeuroOne Medical Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageNeuroOne Medical Technologies has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.40% of the float of NeuroOne Medical Technologies has been sold short.Short Interest Ratio / Days to CoverNeuroOne Medical Technologies has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeuroOne Medical Technologies has recently decreased by 15.55%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeuroOne Medical Technologies does not currently pay a dividend.Dividend GrowthNeuroOne Medical Technologies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NMTC. Previous Next 2.2 News and Social Media Coverage News SentimentNeuroOne Medical Technologies has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for NeuroOne Medical Technologies this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added NeuroOne Medical Technologies to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NeuroOne Medical Technologies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.50% of the stock of NeuroOne Medical Technologies is held by insiders.Percentage Held by InstitutionsOnly 16.07% of the stock of NeuroOne Medical Technologies is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of NeuroOne Medical Technologies is -1.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeuroOne Medical Technologies is -1.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuroOne Medical Technologies has a P/B Ratio of 4.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad TranzactWhat is Medicare Supplement Insurance?Original Medicare helps covers a lot of hospital and medical services, but it still leaves some out- of- pocket medical costs to recipients. Make sure your family’s nest egg is protected from unpredictable medical expenses. Consider applying for a Medicare Supplement Insurance Plan that travels with you. Learn More Here About NeuroOne Medical Technologies Stock (NASDAQ:NMTC)NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.Read More NMTC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NMTC Stock News HeadlinesApril 11, 2024 | stockhouse.comNeuroOne® Announces First Implant of OneRF(TM) Ablation ElectrodesApril 10, 2024 | globenewswire.comNeuroOne® CEO Dave Rosa Featured on Bloomberg TechnologyApril 26, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…April 9, 2024 | globenewswire.comNeuroOne® Announces First Implant of OneRF™ Ablation ElectrodesApril 4, 2024 | finance.yahoo.comNeuroOne® CEO Dave Rosa Featured on Fox Business Network’s Varney & Co.April 4, 2024 | globenewswire.comNeuroOne® CEO Dave Rosa Featured on Fox Business Network's Varney & Co.March 28, 2024 | stockhouse.comNeuroOne® Initiates Limited Commercial Launch of OneRF(TM) Ablation SystemMarch 26, 2024 | finance.yahoo.comNeuroOne® Initiates Limited Commercial Launch of OneRF™ Ablation SystemApril 26, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.March 22, 2024 | investing.comNeuroone Medical Technologies Corp (NMTC)March 17, 2024 | ca.finance.yahoo.comNMTC Jul 2024 2.500 callMarch 8, 2024 | globenewswire.comNeuroOne® to Participate in the 36th Annual Roth ConferenceFebruary 24, 2024 | finanznachrichten.deNeuroOne Medical Technologies Corp: NeuroOne Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)February 23, 2024 | globenewswire.comNeuroOne Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)February 16, 2024 | finanznachrichten.deNeuroOne Medical Technologies Corp: NeuroOne Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdateFebruary 16, 2024 | finance.yahoo.comNeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q1 2024 Earnings Call TranscriptFebruary 16, 2024 | seekingalpha.comNeuroOne Medical Technologies Corporation (NMTC) Q1 2024 Earnings Call TranscriptFebruary 15, 2024 | markets.businessinsider.comNeuroOne Medical Technologies Corporation Registered ShsFebruary 15, 2024 | finance.yahoo.comNeuroOne Medical Technologies First Quarter 2024 Earnings: Revenues Beat Expectations, EPS In LineFebruary 13, 2024 | msn.comNeuroOne Medical Technologies GAAP EPS of -$0.14February 13, 2024 | finance.yahoo.comNeuroOne® Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdateFebruary 12, 2024 | markets.businessinsider.comNeuroOne Medical Technologies earnings: here's what Wall Street expectsFebruary 8, 2024 | finance.yahoo.comNeuroOne® to Report First Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on February 13January 24, 2024 | wsj.comNeuroOne Medical Technologies Corp.December 19, 2023 | finance.yahoo.comNeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q4 2023 Earnings Call TranscriptDecember 15, 2023 | finanznachrichten.deNeuroOne Medical Technologies Corp: NeuroOne Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate UpdateDecember 14, 2023 | finance.yahoo.comNeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate UpdateSee More Headlines Receive NMTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroOne Medical Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/13/2024Today4/26/2024Next Earnings (Estimated)5/09/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NMTC CUSIPN/A CIK1500198 Webwww.originalsourcemusic.com Phone(952) 426-1383FaxN/AEmployees16Year FoundedN/APrice Target and Rating Average Stock Price Target$2.20 High Stock Price Target$2.20 Low Stock Price Target$2.20 Potential Upside/Downside+98.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,860,000.00 Net Margins-478.41% Pretax Margin-478.37% Return on Equity-267.82% Return on Assets-200.46% Debt Debt-to-Equity RatioN/A Current Ratio3.68 Quick Ratio2.52 Sales & Book Value Annual Sales$2.82 million Price / Sales10.22 Cash FlowN/A Price / Cash FlowN/A Book Value$0.26 per share Price / Book4.27Miscellaneous Outstanding Shares25,931,000Free Float23,986,000Market Cap$28.78 million OptionableOptionable Beta0.81 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. David A. Rosa M.D. (Age 60)President, CEO & Director Comp: $759.98kMr. Ronald W. McClurg (Age 64)Chief Financial Officer Comp: $358.79kMr. Steven Mertens (Age 61)Chief Technology Officer Comp: $332.26kMr. Mark Christianson (Age 57)Co-Founder, Business Development Director & Medical Sales Liaison Comp: $260.85kMr. Christopher R. Volker CFAChief Operating OfficerMr. Hijaz HarisVice President of MarketingMore ExecutivesKey CompetitorsFemasysNASDAQ:FEMYSpectral AINASDAQ:MDAISeaStar MedicalNASDAQ:ICUModular MedicalNASDAQ:MODDLucid DiagnosticsNASDAQ:LUCDView All CompetitorsInsidersMark ChristiansonSold 6,848 sharesTotal: $9,244.80 ($1.35/share)Mark ChristiansonSold 9,907 sharesTotal: $13,869.80 ($1.40/share)Christopher VolkerBought 75,000 shares on 12/21/2023Total: $105,000.00 ($1.40/share)Ronald W McclurgBought 50,900 shares on 9/13/2023Total: $49,882.00 ($0.98/share)View All Insider Transactions NMTC Stock Analysis - Frequently Asked Questions Should I buy or sell NeuroOne Medical Technologies stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeuroOne Medical Technologies in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NMTC shares. View NMTC analyst ratings or view top-rated stocks. What is NeuroOne Medical Technologies' stock price target for 2024? 1 brokerages have issued 12 month target prices for NeuroOne Medical Technologies' shares. Their NMTC share price targets range from $2.20 to $2.20. On average, they anticipate the company's stock price to reach $2.20 in the next year. This suggests a possible upside of 98.2% from the stock's current price. View analysts price targets for NMTC or view top-rated stocks among Wall Street analysts. How have NMTC shares performed in 2024? NeuroOne Medical Technologies' stock was trading at $1.58 at the beginning of 2024. Since then, NMTC shares have decreased by 29.7% and is now trading at $1.11. View the best growth stocks for 2024 here. Are investors shorting NeuroOne Medical Technologies? NeuroOne Medical Technologies saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 308,500 shares, a decrease of 15.5% from the March 31st total of 365,300 shares. Based on an average daily trading volume, of 194,700 shares, the days-to-cover ratio is presently 1.6 days. Approximately 1.4% of the shares of the stock are sold short. View NeuroOne Medical Technologies' Short Interest. When is NeuroOne Medical Technologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our NMTC earnings forecast. How were NeuroOne Medical Technologies' earnings last quarter? NeuroOne Medical Technologies Co. (NASDAQ:NMTC) released its earnings results on Tuesday, February, 13th. The company reported ($0.14) earnings per share for the quarter. The company earned $0.98 million during the quarter. NeuroOne Medical Technologies had a negative trailing twelve-month return on equity of 267.82% and a negative net margin of 478.41%. How do I buy shares of NeuroOne Medical Technologies? Shares of NMTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NMTC) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve GoldBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroOne Medical Technologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
